International Stem Cell CORP (OTC:ISCO)

About ISCO

International Stem Cell Corporation (ISCO) is a clinical-stage biotechnology firm dedicated to creating therapeutic and biomedical solutions for a global market, spanning North America, Asia, Europe, and beyond. Central to its offerings are products derived from its proprietary human parthenogenetic stem cells, a unique form of pluripotent stem cells. ISCO is actively engaged in developing specialized cell types, such as neural stem cells, which hold promise for treating Parkinson's disease and other disorders affecting the central nervous system. Beyond therapeutics, the company also develops, manufactures, and commercializes anti-aging skincare products and an extensive range of human cell culture products. Its diverse portfolio of human cell culture products serves as vital research tools across numerous scientific disciplines. This includes specialized cells and reagents designed for studying: Dermatology: Skin diseases, toxicology, and wound healing. Cardiovascular & Oncology: Heart and blood vessel conditions, and various cancers. Respiratory: Bronchial and tracheal conditions, toxicity, cystic fibrosis, asthma, and pathogenesis. Reproductive & Urological: Prostate, renal, bladder, corneal, and female reproductive system diseases, as well as general cellular physiology. Musculoskeletal & Metabolic: Skeletal muscle biology, diabetes, insulin pathways, muscle repair, and myotube development. The company also provides adult stem cells for regenerative medicine research and a full complement of reagents and supplements essential for cell growth, staining, and cryopreservation. Distribution of ISCO's skincare range occurs via its website and specialized professional channels, while its human cell culture products reach customers through a dedicated sales force, original equipment manufacturer (OEM) partners, and authorized brand distributors. Established in 2001, International Stem Cell Corporation maintains its headquarters in San Diego, California.